<DOC>
	<DOC>NCT00403793</DOC>
	<brief_summary>Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.</brief_summary>
	<brief_title>Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)</brief_title>
	<detailed_description />
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>Male Mentally and physically healthy BMI between 18 and 32 kg/m^2 Two pretreatment semen samples &gt; 20 million/ml with normal morphology and motility History or presence of psychiatric disease, liver disease, renal disease, diabetes, cardiovascular disease, any malignancy, prostatic disease, or genitourinary infection PSA &gt; 2.5 ng/ml Use of drugs known to interfere with pharmacokinetics of steroids Use of lipidlowering drugs</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>